- Home
- ME
as 03-13-2025 4:00pm EST
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | SUNNYVALE |
| Market Cap: | 40.0M | IPO Year: | N/A |
| Target Price: | $9.40 | AVG Volume (30 days): | 466.4K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -15.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.34 - $12.76 | Next Earning Date: | 01-28-2025 |
| Revenue: | $208,775,000 | Revenue Growth: | -15.81% |
| Revenue Growth (this year): | 22% | Revenue Growth (next year): | 17.31% |
Latest 23andMe Holding Co. News
ME Breaking Stock News: Dive into ME Ticker-Specific Updates for Smart Investing
GuruFocus.com
4 days ago
23andMe's Wild Ride: From $6 Billion to Wojcicki's Buyout Gamble--Will Investors Get Screwed?
MT Newswires
10 days ago
23andMe Rejects CEO's New Acquisition Proposal
The Wall Street Journal
10 days ago
23andMe Rejects CEO’s Takeover Bid of 41 Cents a Share
GlobeNewswire
11 days ago
23andMe Special Committee Rejects Acquisition Proposal From CEO Anne Wojcicki
Fortune
13 days ago
A few years ago 23andMe was worth $6 billion. Now CEO Anne Wojcicki is trying to buy it back for $42 million
GlobeNewswire
a month ago
23andMe Launches New Genetic Report on Osteoporosis
Quartz
a month ago
Trump's Medicaid freeze, Ozempic for kidney disease, and 23andMe for sale: Pharma news roundup
MedTech Dive
a month ago
23andMe considers sale as cash runs low
Compare ME vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ME 23andMe Holding Co. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.